ORCA Therapeutics

Executive Summary

ORCA Therapeutics is a clinical-stage biopharmaceutical company based in Leiden, Netherlands, focused on developing oncolytic virus immunotherapies for prostate cancer. Founded in 2016, the company's lead candidate, ORCA-010, is a genetically modified adenovirus designed to selectively replicate in and destroy cancer cells while stimulating an anti-tumor immune response. ORCA-010 is currently being evaluated in a Phase I/IIa clinical trial, with initial safety and efficacy data expected to read out within the next 12–18 months. The company's approach leverages the inherent advantages of oncolytic viruses, including tumor selectivity, immune activation, and potential for combination with other therapies. While still in early clinical development, ORCA Therapeutics represents a promising player in the oncology space, with a differentiated platform targeting a significant unmet need in prostate cancer. The company is privately held and has not disclosed total funding or valuation, but its progress in the clinic positions it for potential partnership or additional financing opportunities as data mature.

Upcoming Catalysts (preview)

• H2 2027Phase I/IIa interim safety and efficacy data readout45% success
• Q1 2027Completion of Phase I/IIa patient enrollment60% success
• TBDPotential partnership or licensing deal for ORCA-01030% success